Best Healthcare ETFs to Buy: June 2026 Edition
Comparing the top-performing healthcare funds by expense ratio, GLP-1 drug exposure, and UnitedHealth concentration risk.
Choosing the best healthcare ETFs in 2026 requires a balanced understanding of defensive stability versus high-growth innovation. As capital rotates away from overextended tech valuations, healthcare has emerged as a primary beneficiary due to its attractive price-to-earnings ratios and the massive tailwind of GLP-1 weight-loss therapeutics. Investors must decide between core large-cap anchors that track the healthcare stocks in the S&P 500 index and more volatile, high-reward baskets found in the complete list of biotechnology companies listed on U.S. exchanges.
While the sector is traditionally considered “defensive,” 2026 has introduced specific regional and regulatory risks, particularly within the managed-care insurance space. For those seeking aggressive growth, leveraged options like the ★ LABU Stock Profile offer exposure to clinical breakthroughs, including developments within the list of small cap cancer stocks. This guide provides a tiered framework to help you select the right fund based on your risk tolerance and interest in the current AI-driven diagnostics and drug-discovery cycle.
Best Healthcare ETFs — 2026 Market Insights
Pharmaceutical-heavy ETFs have significantly outperformed service-provider funds in 2026, driven by Eli Lilly and Novo Nordisk’s weight-loss drug dominance.
Insurers like UnitedHealth (UNH) face regulatory headwinds and rising medical loss ratios, making insurance-specific ETFs (IHF) more volatile than broad sector funds.
Funds like VHT provide 400+ holdings for total diversification, while XLV focuses on the top 60-70 mega-caps, leading to higher single-stock concentration risk.
Equal-weighted funds (XBI) are outperforming market-cap-weighted biotech (IBB) in 2026 as M&A activity targets small-cap innovators rather than established giants.
Top 10 Healthcare ETFs Compared
| ETF Name | Ticker | Expense | Div Yield | 1Y Return | 5Y Return | Best For |
|---|---|---|---|---|---|---|
| Health Care Select Sector SPDR | XLV | 0.08% | 1.50% | 11.67% | 7.50% | Core Portfolio Large-Cap |
| Vanguard Healthcare ETF | VHT | 0.09% | 1.43% | 16.75% | 7.49% | Total Sector Coverage |
| iShares U.S. Medical Devices | IHI | 0.40% | 0.55% | 14.10% | 6.20% | Surgical Robotics & Hardware |
| SPDR S&P Biotech ETF | XBI | 0.35% | 0.20% | 22.40% | -1.10% | High-Upside Small-Cap Biotech |
| iShares Biotechnology ETF | IBB | 0.45% | 0.38% | 12.80% | 3.90% | Mega-Cap Biotech Stability |
| iShares U.S. Healthcare ETF | IYH | 0.40% | 1.17% | 11.50% | 7.40% | Liquid Alternative Indexing |
| Fidelity MSCI Health Care | FHLC | 0.08% | 1.45% | 16.50% | 7.35% | Retail Buy-and-Hold |
| iShares Global Healthcare | IXJ | 0.40% | 1.44% | 4.38% | 5.41% | International Drug Makers |
| Invesco S&P 500 Equal Weight Health | RSPH | 0.40% | 1.10% | 8.90% | 5.15% | Mitigating Concentration Risk |
| iShares U.S. Healthcare Providers | IHF | 0.40% | 1.05% | -4.20% | 6.80% | Insurance & Managed Care |
Our Top Pick: Health Care Select Sector SPDR (XLV)
XLV offers institutional-grade liquidity and the lowest expense ratio in the category. It captures the highly profitable, cash-flow-rich leaders of the S&P 500 healthcare sector.
Holds ~$40B in assets with a healthy 1.50% dividend yield. Top holdings include Eli Lilly, UnitedHealth, and Johnson & Johnson.
Conservative investors seeking a defensive anchor that provides both capital appreciation and growing dividend income.
High concentration in the top 10 holdings (over 50% of the fund), making it sensitive to single-stock volatility like UNH or LLY price swings.
Top Healthcare ETF Reviews
Health Care Select Sector SPDR
XLVVanguard Healthcare ETF
VHTiShares U.S. Medical Devices ETF
IHISPDR S&P Biotech ETF
XBIiShares Biotechnology ETF
IBBFidelity MSCI Health Care Index ETF
FHLCiShares Global Healthcare ETF
IXJInvesco S&P 500 Equal Weight Health Care
RSPHHow to Choose the Best Healthcare ETF
The healthcare landscape of 2026 is split between two massive themes: the “Pills” (Pharma/Biotech) and the “Providers” (Managed Care/Hospitals). Your choice of ETF determines which of these trends you are betting on.
The UnitedHealth (UNH) Factor
UnitedHealth is the massive “elephant” in almost every broad healthcare ETF. As of June 2026, UNH accounts for roughly 10-12% of XLV. If you believe the insurance sector is over-regulated or facing rising costs, you should look toward equal-weighted funds (RSPH) or pure biotech funds (XBI) to dilute this specific exposure.
GLP-1 and Pharma Innovation
For exposure to the obesity and diabetes drug market, focus on funds with heavy Eli Lilly (LLY) and AbbVie (ABBV) weightings. Funds like XLV and IYH are currently dominated by these pharmaceutical leaders. Conversely, if you want to avoid the “high-valuation pharma” trade, medical device funds like IHI provide a more hardware-centric alternative.
What to Avoid in Healthcare Investing
Managed Care Concentration
Avoid funds like IHF unless you have a high conviction in the insurance industry. Managed care is currently facing significant margin compression due to rising medical costs and government reimbursement cuts.
Clinical Trial Binary Risk
Biotech ETFs, especially equal-weighted ones, are subject to “binary events”—success or failure of drug trials that can cause 20% swings in a single day. Only allocate capital you can afford to lose.
Regulatory Overhang
Drug-pricing legislation (like the Inflation Reduction Act’s negotiation clauses) poses a long-term threat to pharmaceutical margins. Ensure your ETF includes non-pharma stocks for balance.
High Turnover Fees
Avoid thematic healthcare ETFs with expense ratios above 0.75%. In a defensive sector, high fees can quickly eat away at the moderate 7-9% annual returns typical of the industry.
